J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care01/08/2025 majac Cancer (Bloomberg) — Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a …Share on FacebookTweetFollow usSave